News coverage about Myokardia (NASDAQ:MYOK) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Myokardia earned a news impact score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.4466932444819 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
MYOK has been the topic of several recent research reports. BidaskClub raised Myokardia from a “hold” rating to a “buy” rating in a research note on Saturday, February 17th. BMO Capital Markets lifted their price target on Myokardia from $65.00 to $83.00 and gave the company an “outperform” rating in a research note on Friday, March 9th. Zacks Investment Research raised Myokardia from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research note on Tuesday, March 13th. Cowen reissued a “buy” rating and issued a $56.00 price target on shares of Myokardia in a research note on Friday, March 9th. Finally, Credit Suisse Group lifted their price target on Myokardia from $60.00 to $68.00 and gave the company an “outperform” rating in a research note on Friday, March 9th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Myokardia presently has a consensus rating of “Buy” and an average price target of $67.29.
NASDAQ:MYOK opened at $48.55 on Thursday. The stock has a market capitalization of $1.75 billion, a P/E ratio of -34.68 and a beta of 3.53. Myokardia has a 52-week low of $12.60 and a 52-week high of $62.83.
Myokardia (NASDAQ:MYOK) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.21). The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $7.82 million. Myokardia had a negative net margin of 235.47% and a negative return on equity of 25.18%. research analysts expect that Myokardia will post -1.72 EPS for the current year.
In other Myokardia news, major shareholder Sanofi purchased 150,000 shares of Myokardia stock in a transaction that occurred on Friday, May 25th. The stock was acquired at an average price of $49.00 per share, for a total transaction of $7,350,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anastasios Gianakakos sold 3,000 shares of Myokardia stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $46.95, for a total value of $140,850.00. Following the transaction, the insider now owns 77,949 shares of the company’s stock, valued at approximately $3,659,705.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,683 shares of company stock worth $760,121. 4.70% of the stock is owned by company insiders.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.